A phase I, open label, dose-escalation study of the safety and pharmacokinetics of Apo2L/TRAIL administered intravenously to subjects with advanced or metastatic solid malignancies, or non-Hodgkin's lymphoma

Trial Profile

A phase I, open label, dose-escalation study of the safety and pharmacokinetics of Apo2L/TRAIL administered intravenously to subjects with advanced or metastatic solid malignancies, or non-Hodgkin's lymphoma

Recruiting
Phase of Trial: Phase I

Latest Information Update: 28 Jul 2006

At a glance

  • Drugs Dulanermin (Primary)
  • Indications Non-Hodgkin's lymphoma; Solid tumours
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 28 Jul 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top